1. Scrip
  2. >>Business
  3. >>Deals

What next for acquisition-hungry Valeant?

 
• By Sukaina Virji

Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time to do a post mortem," according to Laurie Little, Valeant's VP of investor relations, speaking at the Jefferies Global Healthcare Conference on 19 November. However, there's "no urgency" to get another big deal going. "We need a few days' rest," she said. "It would be good to string a few quiet quarters together."

Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time to do a post mortem," according to Laurie Little, Valeant's VP of investor relations, speaking at the Jefferies Global Healthcare Conference on 19 November. However, there's "no urgency" to get another big deal going. "We need a few days' rest," she said. "It would be good to string a few quiet quarters together."

But of course, this is Valeant, and Ms Little acknowledged that Valeant's business development team was "active" even while Allergan was ongoing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.